New antidepressants: monoamines and beyond

Greener, M.

Greener, M..

Prescriber ; 34(1):17-20, 2023.

Article Dans Anglais | EMBASE | ID: covidwho-2261258

ABSTRACT

ABSTRACT

The monoamine hypothesis of depression has dominated treatment for decades, but for some with treatment-resistant depression, alternative approaches are needed. This article discusses some of the other mechanisms involved in depression and how novel treatments could address these.Copyright © 2023 Wiley Interface Ltd.

Mots clés

anhedonia, article, autoimmunity, cardiovascular disease, central nervous system, cognition, cognitive behavioral therapy, coronavirus disease 2019, depression, glutamatergic signaling, Hamilton Depression Rating Scale, human, inflammation, learning, lifestyle, memory, microglia, nerve cell plasticity, neurotoxicity, pandemic, positron emission tomography, prefrontal cortex, psychotherapy, quality of life, Rauvolfia serpentina, antidepressant agent, biological marker/ec [Endogenous Compound], C reactive protein/ec [Endogenous Compound], duloxetine, glucocorticoid, interleukin 1beta/ec [Endogenous Compound], interleukin 6/ec [Endogenous Compound], iproniazid, isoniazid, ketamine, monoamine, neurotransmitter/ec [Endogenous Compound], noradrenalin, psilocybine, psychedelic agent, serotonin 2A receptor/ec [Endogenous Compound], serotonin uptake inhibitor/ec [Endogenous Compound], venlafaxine

Texte intégral

Imprimer

XML

Texte intégral: Disponible Collection: Bases de données des oragnisations internationales Base de données: EMBASE langue: Anglais Revue: Prescriber Année: 2023 Type de document: Article

Documents relatifs à ce sujet

MEDLINE

LILACS

LIS

Texte intégral

Imprimer

XML